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ABSTRACT
Background The proinflammatory cytokines interleukin
1b (IL-1b) and IL-18 are central players in the
pathogenesis of inflammatory bowel disease (IBD). In
response to a variety of microbial components and
crystalline substances, both cytokines are processed via
the caspase-1-activating multiprotein complex, the
NLRP3 inflammasome. Here, the role of the NLRP3
inflammasome in experimental colitis induced by dextran
sodium sulfate (DSS) was examined.
Methods IL-1b production in response to DSS was
studied in macrophages of wild-type, caspase-1e/e,
NLRP3e/e, ASCe/e, cathepsin Be/e or cathepsin Le/e
mice. Colitis was induced in C57BL/6 and NLRP3e/e
mice by oral DSS administration. A clinical disease
activity score was evaluated daily. Histological colitis
severity and expression of cytokines were determined in
colonic tissue.
Results Macrophages incubated with DSS in vitro
secreted high levels of IL-1b in a caspase-1-dependent
manner. IL-1b secretion was abrogated in macrophages
lacking NLRP3, ASC or caspase-1, indicating that DSS
activates caspase-1 via the NLRP3 inflammasome.
Moreover, IL-1b secretion was dependent on
phagocytosis, lysosomal maturation, cathepsin B and L,
and reactive oxygen species (ROS). After oral
administration of DSS, NLRP3e/e mice developed a less
severe colitis than wild-type mice and produced lower
levels of proinflammatory cytokines in colonic tissue.
Pharmacological inhibition of caspase-1 with pralnacasan
achieved a level of mucosal protection comparable with
NLRP3 deficiency.
Conclusions The NLRP3 inflammasome was identified
as a critical mechanism of intestinal inflammation in the
DSS colitis model. The NLRP3 inflammasome may serve
as a potential target for the development of novel
therapeutics for patients with IBD.
INTRODUCTION
Human inflammatory bowel disease (IBD), the
most important entities being ulcerative colitis and
Crohn’s disease, are chronic, relapsing and remit-
ting inflammatory conditions that result from
chronic dysregulation of the mucosal immune
system in the gastrointestinal tract.1 The precise
pathogenesis of IBD is still incompletely under-
stood. However, it is now widely accepted that
genetic and environmental factors are involved.
Animal models of experimental colitis have been
developed to investigate the molecular and cellular
mechanisms leading to IBD, and these models are
frequently used to develop and evaluate the efficacy
of novel anti-inflammatory drugs. In the acute
dextran sodium sulfate (DSS) colitis model mice
are fed with DSS polymers in the drinking water
and this induces a colitis characterised by diar-
rhoea, bloody faeces, weight loss and a histological
picture of inflammation and ulceration as seen in
human IBD.2 As the acute inflammatory response
is independent of T and B cells,3 the model is
particularly useful to study the contribution of
innate immune mechanisms in intestinal inflam-
mation and, presumably due to toxic effects of DSS
on the mucosa, epithelial barrier dysfunction.
Increased levels of proinflammatory cytokines,
including interleukin-1b (IL-1b), IL-6, IL-18 and
tumour necrosis factor a (TNFa), are detected in
active IBD and correlate with the severity of
inflammation.4e6 IL-1b and TNFa have been
shown to alter tight junctions and intestinal
permeability.7 As epithelial barrier integrity is
essential for blocking the access of microorganisms
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and toxins to underlying tissues, IL-1b is likely to be essential in
the early phase of the inflammatory cascade leading to an
inflamed colon. Indeed, enhanced levels of IL-1b are found in
colonic mucosa and peritoneal macrophages in DSS-induced
colitis and may hence represent an initial trigger of intestinal
inflammation.8 IL-1b and IL-18 are activated by caspase-1, and
studies with caspase-1e/e mice strongly suggest that caspase-1
plays a key role in DSS-induced colitis.9
The NLR (nucleotide-binding domain and leucine-rich repeat-
containing) family comprises a group of intracellular pattern
recognition receptors. NLRs have a leucine-rich repeat (LRR) that
recognises diverse pathogen-associated molecular patterns.10
NOD2 and NLRP3 are two of the best characterised NLRs, and
mutations of these receptors have been linked to Crohn’s disease.
NOD2 recognises the bacterial peptidoglycan-derived molecule
muramyl dipeptide (MDP) and activates the nuclear factor-kB
(NF-kB) pathway to induce an inflammatory response. Muta-
tions of the NOD2 gene have been identified in individuals
with Crohn’s disease.11 12 These polymorphisms have been
linked to NF-kB activation and IL-1b secretion.13 However, the
exact interaction of NOD2, NF-kB and pro-IL-1b/IL-1b remains
a matter of debate.14 NLRP3, also known as cryopyrin, forms an
inflammasome with the adaptor molecule ASC and caspase-1 to
convert pro-IL-1b and pro-IL-18 into their active forms. Muta-
tions in NLRP3 lead to chronic autoinflammatory syndromes.15
Single nucleotide polymorphisms (SNPs) in the NLRP3 gene
region are associated with susceptibility to Crohn’s disease.16 In
addition, the combination of polymorphisms in NLRP3 and
CARD8 was recently shown to be associated with Crohn’s
disease in Swedish male subjects.17
Recent studies have identified the autophagy protein Atg16L1
as a further susceptibility factor for Crohn’s disease.18 19
Notably, Atg16L1 deficiency causes Toll/IL-1 receptor domain-
containing adaptor inducing interferon b (TRIF)-dependent
activation of caspase-1, and mice lacking Atg16L1 in haemato-
poietic cells are highly susceptible to DSS-induced acute colitis.20
Elevated systemic IL-1b and IL-18 levels in these mice correlated
with severe mucosal inflammation, pointing towards an
important role for deregulated caspase-1 activity in the patho-
genesis of both IBD and DSS-induced colitis.9
In this study, we investigated the regulation of caspase-1 acti-
vation in response to DSS in murine macrophages with genetic
deletions of NLRP3 inflammasome components. In addition, the
role of the NLRP3 inflammasome in intestinal inflammation was
investigated using the acute DSS colitis model.
METHODS
Cell culture and reagents
Macrophage cell lines of wild-type (WT), caspase-1e/e, NLRP3e/e,
ASCe/e, cathepsin Be/e, cathepsin Le/e and IPAFe/e mice were
generated as described.21 Cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) high glucose supplemented with 1%
L-glutamine (all PAA, Pasching, Austria), 10% fetal calf serum
(FCS; GIBCO, Karlsruhe, Germany) and 10 mg/ml ciprofloxacin
(Hexal, Holzkirchen, Germany). Human THP-1 cells were culti-
vated in RPMI supplemented with 10% FCS, 1% Na-pyruvate
and 10 mg/ml ciprofloxacin, and differentiated with phorbol
12-myristate 13-acetate (PMA; 5 nM) 3 h before DSS stimulation.
Primary human macrophages were generated from adherent
peripheral blood mononuclear cells (PBMCs) of healthy donors
and cultivated in RPMI with 2% AB serum (Lonza, Verviers,
Belgium), 1% L-glutamine, 100 U/ml penicillin, 0.1 mg/ml strep-
tomycin (PAA, Pasching, Austria) in the presence of 1000 U/ml
recombinant human granulocyte-stimulating factor (rhGM-CSF;
Berlex, Richmond, California, USA). The caspase-1 inhibitor
z-YVAD-fmk, nigericin, cytochalasin D and bafilomycin A1 were
purchased from Calbiochem (Darmstadt, Germany). Poly(dA:dT)
sodium salt, N-acetyl-L-cysteine (NAC), ammonium pyrrolidine-
dithiocarbamate (APDC) and dextranase were from Sigma-Aldrich
(Munich, Germany). All DSS reagents were from MP Biomedicals
(Illkirch, France). Ultra pure lipolysaccharide (LPS) K12 and
acridine orange were from Invitrogen (Toulouse, France). The
caspase-1 inhibitor pralnacasan was provided by Sanofi-Aventis
(Frankfurt, Germany). Cremophor EL was purchased from BASF
(Ludwigshafen, Germany).
Speck formation assay
Assembly of the ASC-containing NLRP3 inflammasome was
studied using macrophages that stably express the fusion protein
ASCecyan fluorescent protein (CFP). Cells were plated at
a density of 106 cells/well, primed with 10 ng/ml LPS for 2 h and
incubated with DSS for 24 h. The cells were washed and
ASCeCFP speck formation was analysed by fluorescence
microscopy (Zeiss, Jena, Germany) and ImageJ software (NIH,
Bethesda, Maryland, USA) for digitally counting specks per high
power field (HPF).
Flow cytometry
For the analysis of lysosomal damage macrophages were plated
into 24-well culture dishes and stimulated for 24 h with DSS.
The cells were washed and incubated with 1 mg/ml acridine
orange for 15 min for staining of lysosomes. Cells were washed
twice and fluorescence intensity was analysed at 600e650 nm
emission wavelength with a FACSCanto II (BD Biosciences San
Diego, California, USA). Data analysis was performed using
FlowJo software (Tree Star, Ashland, Oregon, USA).
Mice
NLRP3e/e mice22 were bred at the University of Munich and
used for experiments between the ages of 8 and 16 weeks. Age-
matched WTcontrols were purchased from Harlan Winkelmann
(Borchen, Germany). Mice were fed standard mice chow pellets,
had access to tap water supplied in bottles, and were acclima-
tised at least 7 days before they entered into experiments. All
experiments were approved by the regional animal study
committee and are in agreement with the guidelines for the
proper use of animals in biomedical research.
Induction of colitis and treatment
Colitis was induced inC57BL/6 andNLRP3e/emicewith 2%DSS
(molecular weight¼40 kDa) dissolved in drinking water given
ad libitum (days 1e9) as described.2 Control mice were given tap
water. The caspase-1 inhibitor pralnacasan was dissolved in 25%
Cremophor EL solution and was filtered through syringe filters
(0.2 mm). The substance was administered intraperitoneally at
a dosage of 50 mg/kg body weight twice daily. Control animals
received Cremophor EL intraperitoneally twice daily.
Clinical score and histological analysis
Body weight, the presence of occult or gross blood per rectum,
and stool consistency were determined by two investigators
blinded to the treatment groups. A scoring systemwas applied to
assess diarrhoea and the presence of occult or overt blood in the
stool.23 Changes of body weight are indicated as loss of baseline
body weight as a percentage. Postmortem, the colon was
removed and pieces of colonic tissue were used for ex vivo anal-
ysis. For histology, rings of the transverse part of the colon were
fixed in 4% buffered formalin and embedded in paraffin. Sections
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were stained with H&E according to standard protocols. Histo-
logical scoring was performed in a blinded way by a pathologist
(HAL). Focally increased numbers of inflammatory cells in the
lamina propria were scored as 1, confluence of inflammatory cells
extending into the submucosa as 2 and transmural extension of
the infiltrate as 3. For tissue damage, discrete lymphoepithelial
lesions were scored as 1, mucosal erosions as 2, and extensive
mucosal damage and/or extension through deeper structures of
the bowel wall as 3. The two equally weighted subscores (cell
infiltration and tissue damage) were added and the combined
histological colitis severity score ranged from 0 to 6.
Ex vivo analysis of colonic cytokines
Strips of colon were mechanically crushed, vortexed in 200 ml of
Tissue Protein Extraction Reagent (Pierce, Rockford, USA) for
1 min and shock frozen in liquid nitrogen. The homogenate was
centrifuged at 10 000 g at 48C for 15 min. The amount of total
extracted protein was determined by Bradford analysis using the
BioRad Protein Assay (BioRad, Munich, Germany). The amount
of IFNg, IL-1b and TNFa in the colon homogenate was
quantified by ELISA (BD Biosciences Pharmingen, San Diego,
California, USA).
mRNA extraction and reverse transcriptionePCR (RTePCR)
Colonic tissue was cleaned in phosphate-buffered saline (PBS),
snap-frozen in liquid nitrogen and stored at e708C. Total cellular
RNA was isolated by homogenising tissue with an Ultra Turrax
instrument (Janke und Kunkel, Staufen im Breisgau, Germany)
and using the Roche Total RNA Tissue Extraction Kit (Roche,
Mannheim, Germany). The yield and purity of the RNA were
determined by spectroscopic analysis and the concentration of
total RNA was equilibrated. For reverse transcription, M-MLV
reverse transcriptase (Gibco Life Technologies, Paisley, UK),
RNase inhibitor (Roche), oligo(dT) primer for cDNA synthesis
(Roche) and dNTP (Promega, Madison, Wisconsin, USA) were
used. A Light Cycler Instrument (Roche) and the Light Cycler
Fast Start DNA Master SYBR Green I Kit (Roche) were used for
real-time PCR, according to the manufacturers recommenda-
tions. Primers for murine glyceraldehyde phosphate dehydroge-
nase (GAPDH) and IP-10 (CXCL-10) were purchased as Light
Cycler Primer Sets including standard DNA from Search-LC
(Heidelberg, Germany). The number of copies in each sample
was correlated with the number of GAPDH copies.
Isolation of peritoneal macrophages
Mice were sacrified by cervical dislocation under isoflurane
anaesthesia, injected with 10 ml of PBS intraperitoneally and,
after shaking, peritoneal lavage was performed. Collected peri-
toneal lavage fluid was centrifuged and erythrocytes in the cell
pellet were lysed using BD Pharm Lyse lysing buffer (BD
Bioscience). The remaining cells were plated into culture dishes
overnight and adherent cells were used for cytokine assays.
ELISA
Primary macrophages and cell lines were seeded into 96-well
plates at a density of 23105 cells per well. After LPS priming for
1 h, cells were stimulated with the indicated amounts of DSS for
24 h. Cell culture supernatant or colon homogenates were used
for ELISAs (BD Bioscience), which were performed according to
the manufacturer ’s protocol.
SDSePAGE and western blotting
Cell culture supernatants of 106 cells or 65 mg of whole protein
from colon homogenate were dissolved in Laemmli buffer
(BioRad) and separated using a 15% acrylamideebisacrylamide
gel. Proteins were blotted onto a 0.45 mm polyvinylidene fluoride
(PVDF) membrane (Millipore, Schwalbach, Germany). Primary
anti-caspase-1 (rabbit, antimouse, Santa Cruz) and anti-IL-1b
(R&D Systems, Wiesbaden-Nordenstadt, Germany) were
applied at 1:500 and horseradish peroxidase (HRP)-coupled
ß-actin (loading control) was used at 1:3000. Immunoglobulin
G (IgG) antigoat-HRP (Santa Cruz) was diluted 1:3000 and
Amersham ECL (GE Healthcare, Munich, Germany) served for
visualisation via chemoluminescence.
Statistical analysis
Data are expressed as means 6 SEM. Statistical significance of
differences between treatment and control groups was deter-
mined by Student t test. Differences were considered statisti-
cally significant at p<0.05.
RESULTS
DSS induces caspase-1-dependent IL-1b processing in murine
macrophages
Release of active IL-1b is mediated by a two-step process initi-
ated by transcriptional induction of pro-IL-1b, for example by
a Toll-like receptor (TLR) stimulus, followed by caspase-1-
mediated cleavage. DSS, a polyanionic derivate of sulfated high
molecular weight dextrane, induces the release of IL-1b from
murine macrophages.8 To investigate the mechanism of IL-1b
release, we incubated a murine macrophage cell line with DSS
for 24 h with or without prior LPS priming. In the absence of
LPS priming, DSS did not induce a notable release of IL-1b.
However, LPS-primed macrophages strongly responded to the
addition of DSS in a dose-dependent manner (figure 1A). The
requirement of LPS priming for enhanced IL-1b synthesis was
further supported by data obtained from a macrophage cell line
of mice with combined MyD88 and TRIF deficiency. These cells
failed to secrete IL-1b in response to either DSS or nigericin,
a potassium ionophore activating caspase-1, but responded
to poly(dA:dT), which induces IL-1b in a TLR-independent
manner (figure 1B). To demonstrate the role of caspase-1 in DSS-
mediated IL-1b release, we incubated the macrophages with the
caspase-1 inhibitor z-YVAD-fmk and found that this completely
abolished the release of IL-1b (figure 1C). Similar results were
obtained using primary peritoneal macrophages from WT mice
(figure 1D) as well as primary human macrophages and THP-1
cells (Supplementary figure 1). To confirm that IL-1b is released
in its active form, we performed western blotting of IL-1b p17
and caspase-1 p10, which were both present in supernatants
of DSS- or nigericin-stimulated macrophages (figure 1E). To
determine whether intact DSS macromolecules were required
for caspase-1 activation, we digested DSS (40 kDa) with
dextranase, which cleaves 1,6-glycosylic bounds of isomaltose,
before macrophage stimulation. Dextranase almost completely
inhibited the release of IL-1b (figure 1F). Incubating macro-
phages with DSS molecules ranging from 8 to 1400 kDa revealed
a positive correlation between IL-1b release and DSS molecular
weight (figure 1G), suggesting that IL-1b secretion is induced
only by intact DSS macromolecules.
DSS induces NLRP3 inflammasome activation
The NLR protein NLRP3 can form an inflammasome complex
with the adaptor molecule ASC and caspase-1 in response to
various stimuli.24 We speculated that caspase-1 activation by
DSS is mediated by the NLRP3 inflammasome. It has been
shown that NLRP3 inflammasome activation is dependent
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on K+ efflux.25 To assess the role of NLRP3 in DSS-induced
caspase-1 activation, we blocked K+ efflux by the addition of
high concentrations of KCl to the extracellular medium and
found that this completely inhibited IL-1b release (figure 2A).
In addition, macrophages lacking NLRP3, ASC or caspase-1
were devoid of IL-1b secretion in response to DSS exposure
(figure 2B). Consistent with previous observations,21 response
to transfected poly(dA:dT) was NLRP3 independent and ASC
dependent. In contrast, macrophages from IPAFe/e mice (IPAF
is an NLRP3-independent, caspase-1-recruiting inflammasome)
showed no defect in IL-1b secretion (figure 2C). The require-
ment of NLRP3 for IL-1b release was further supported by
studying primary peritoneal macrophages from NLRP3e/e mice
(figure 2D). NLRP3 activation triggers the formation of a large
assembly of ASC, which rapidly activates caspase-1. To analyse
the recruitment of ASC, we used macrophages stably
expressing ASC fused to the fluorescent protein CFP.26
NLRP3eASC assembly results in the formation of fluorescent
specks, which can be visualised by fluorescence microscopy.
DSS induced speck formation in a dose-dependent manner
(figure 2E). We could rule out that DSS, either directly or
indirectly, induces NLRP3 inflammasome activation via the
P2X7 receptor27 by demonstrating that IL-1b secretion in
response to DSS was unimpaired in macrophages lacking
P2X7 (figure 2F). Together, these findings indicate that DSS
activates the NLRP3eASC complex, leading to the activation of
caspase-1 and subsequent cleavage of pro-IL-1b into the mature,
secreted form.
NLRP3 inflammasome activation in response to DSS is
dependent on lysosomal maturation and reactive oxygen species
(ROS)
Phagocytosis of particulate danger-associated molecular patterns
has been shown to activate the NLRP3 inflammasome via lyso-
somal destabilisation.21 To characterise the mechanisms
of NLRP3 inflammasome activation in response to DSS further,
we used pharmacological inhibitors to block pathways of lyso-
some formation and function. The role of phagosome formation
in caspase-1 activation was studied by incubating macrophages
prior to DSS stimulation with cytochalasin D, which inhibits
phagocytosis by disrupting actin filaments. Cytochalasin D
completely abrogated IL-1b secretion in response to DSS,
whereas the response to the potassium ionophore nigericin was
unaffected (figure 3A). Moreover, blocking lysosomal acidification
with bafilomycin A1, an inhibitor of the vacuolar H+ ATPase,
completely inhibited DSS-mediated IL-1b release (figure 3A).
These findings suggest a critical role for functional lysosomes in
DSS-mediated NLRP3 activation. Experiments using specific
inhibitors of cathepsin B have shown a link between lysosomal
cysteine proteinases and NLRP3 inflammasome activation for
crystals and influenza virus.21 28 To assess whether this mecha-
nism is operative during DSS-mediated NLRP3 inflammasome
Figure 1 Dextran sodium sulfate (DSS) induces caspase-1-mediated interleukin 1b (IL-1b) release from murine macrophages. (A) Macrophages were
treated with increasing concentrations of DSS in the absence or presence of lipopolysaccharide (LPS) priming. IL-1b was determined in the
supernatant by ELISA. (B) Absence of IL-1b release of LPS-primed MyD88/TRIF-deficient macrophages in response to DSS or nigericin. Transfected
dAdT served as a MyD88/TRIF-independent stimulus. (C) Influence of the caspase-1 inhibitor z-YVAD-fmk (10 mM) on IL-1b release by a macrophage
cell line and (D) by primary macrophages. (E) Western blot analysis of IL-1b p35 and caspase-1 p45 in cell lysates (CL) and of bioactive IL-1b p17 and
caspase-1 p10 in supernatants (SN) of DSS- or nigericin-stimulated, LPS-primed macrophages. (F) Influence of dextranase treatment of DSS on IL-1b
release by macrophages. (G) Influence of DSS molecule size (8 to 1400 kDa) on IL-1b release. Shown are representative data as means 6 SEM (n¼3
independent experiments). *p<0.05. TRIF, Toll/IL-1 receptor domain-containing adaptor inducing interferon b.
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activation, we compared IL-1b release of the WT with that
of cathepsin B- and cathepsin L-deficient macrophages. IL-1b
secretion in DSS-treated macrophages was significantly reduced
in cathepsin B- and, to a lesser extent, in cathepsin L-deficient
macrophages (figure 3B). Thus, lysosomal proteases appear to be
involved in DSS-induced NLRP3 inflammasome activation. We
next assessed whether DSS leads to lysosomal damage, as has
been proposed for crystalline structures.21 We made use of the
staining properties of acridine orange, a dye with green fluores-
cence in its monomeric state and red fluorescence when forming
dimers in acidic compartments, the red fluorescence intensity
correlating with the cytoplasmic number of lysosomes. Indeed,
DSS induced a loss of red fluorescence of macrophages stained
with acridine orange at similar levels to those previously
reported for crystals,21 suggesting lysosomal damage (figure 3C).
Taken together, these findings point towards a DSS-mediated
phagosomal destabilisation, leading to the release of phagosomal
contents into the cytosol where they are sensed by the NLRP3
inflammasome.
NLRP3 inflammasome activation has been linked with ROS
generation in response to various stimuli.28 29 DSS has previ-
ously been shown to stimulate macrophage ROS production.30
To investigate the role of ROS in DSS-induced IL-1b release, we
treated macrophages with the ROS inhibitors N-acetylcysteine
(NAC) and ammonium pyrrolidinedithiocarbamate (APDC).
Both inhibitors significantly reduced IL-1b secretion (figure 3D).
These data suggest that ROS contribute to DSS-induced NLRP3
inflammasome activation.
Figure 3 Activation of the NLRP3
inflammasome by dextran sodium
sulfate (DSS) requires lysosomal
maturation and reactive oxygen species
(ROS). (A) Macrophages were
incubated with cytochalasin D (2 mM)
or bafilomycin A1 (20 nM) before
treatment with 3% DSS. The potassium
ionophore nigericin served as positive
control. Interleukin 1b (IL-1b) was
determined by ELISA. (B) Macrophage
cell lines from wild-type (WT),
cathepsin Be/e or cathepsin Le/e mice
were primed with lipopolysaccharide
(LPS) and incubated with DSS. (C)
Phagosomes of DSS-treated
macrophages were stained with the
fluorochrome acridine orange. Loss of
fluorescence, which correlates with
reduced numbers of lysosomes, was
analysed by fluorescence-activated cell
sorting. (D) Influence of the ROS
inhibitors, ammonium
pyrrolidinedithiocarbamate (APDC) and
N-acetyl-L-cysteine (NAC), on DSS-induced
IL-1b production. Nigericin served as a
positive control. Shown are representative
data as means 6 SEM (n¼3 independent experiments). *p<0.05.
Figure 2 Interleukin 1b (IL-1b)
processing in response to dextran
sodium sulfate (DSS) is mediated by the
NLRP3 inflammasome. (A)
Macrophages were primed with
lipopolysaccharide (LPS) and incubated
with 3% DSS in the presence or absence
of high concentrations of KCl (130 mM).
IL-1b was determined in the supernatant
by ELISA. (B) LPS-primed
macrophage cell lines from wild-
type (WT), NLRP3e/e, ASCe/e or
caspase-1e/e mice were incubated with
3% DSS. Incubation with dAdT served
as a NLRP3-independent, but ASC-
dependent stimulus. (C) IL-1b secretion
by macrophages deficient in the IPAF
inflammasome. (D) IL-1b secretion in
response to 3% DSS by primary
macrophages from WT and NLRP3e/e
mice. (E) Recruitment of ASC to the
inflammasome was visualised using macrophages expressing an ASCecyan fluorescent protein (CFP) fusion protein by fluorescence microscopy. The
numbers of specks per high power field (HPF) were counted. (F) IL-1b secretion by macrophages deficient in the P2X7 receptor. Shown are
representative data as means 6 SEM (n¼3 independent experiments). *p<0.05.
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Colitis severity and inflammatory response in the DSS model
depend on NLRP3 signalling
We next investigated the role of the NLRP3 inflammasome
in DSS-mediated intestinal inflammation in vivo. WT and
NLRP3e/e mice received 2% DSS in their drinking water for a
period of 9 days. Clinical parameters, including body weight, the
presence of occult or gross blood per rectum and stool consis-
tency, were determined daily. NLRP3e/e mice were significantly
protected from DSS-induced colitis, showing reduced loss of
body weight and haematochezia (figure 4A). Of note, four out of
15 WT mice had died due to colitis by day 9, whereas all 15
NLRP3e/e mice survived. Histological analysis of colonic tissue
obtained on day 6 revealed less severe mucosal infiltration by
inflammatory cells and reduced tissue damage in NLRP3e/e
mice, translating into a significantly improved histological colitis
severity score (figure 4B and Supplementary figure 2). On day 9,
histology showed severe intestinal inflammation with destruc-
tion of the epithelial layer leading to identical histology scores in
WT and NLRP3e/e mice, despite the reduced clinical colitis
scores in NLRP3e/emice. These findings indicate that the NLRP
inflammasome plays a more critical role during the early phase
of colitis induction, but cannot prevent colitis progression after
prolonged DSS exposure. As caspase-1 activity is regulated by
NLRP3, inhibition of caspase-1 could be an effective novel
treatment strategy for IBD. In line with this notion, we have
previously reported that pharmacological inhibition of caspase-1
with pralnacasan is effective in the treatment of DSS-induced
experimental colitis.23 Treatment of mice with pralnacasan, at
a dose that had been optimal in our previous study, improved
clinical parameters, such as body weight, stool consistency and
haematochezia (figure 4C). Indeed, the magnitude of the ther-
apeutic benefit was similar to the protective effect observed in
NLRP3e/e mice, providing further evidence that caspase-1 acti-
vation via the NLRP3 inflammasome is a major pathological
mechanism in DSS-induced colitis.
Proinflammatory cytokines, including IL-1b, TNFa and IFNg,
are elevated in colonic tissue in humans and in the acute DSS
colitis model. To assess the influence of the NLRP3 inflamma-
some on the intestinal inflammatory response, we first analysed
IL-1b production of peritoneal macrophages isolated from mice
receiving DSS in their drinking water. Macrophages of WT
mice spontaneously released low levels of IL-1b, which was
strongly enhanced by DSS feeding. In contrast, macrophages of
NLRP3e/e mice secreted no detectable levels of IL-1b in the
absence of DSS feeding and only low levels in response to DSS
(figure 5A). Furthermore, levels of TNFa, IFNg and IP-10 in
colonic homogenates were elevated in WT but not in NLRP3e/e
mice in response to 6 days of DSS feeding (figure 5B). Interest-
ingly, levels of these cytokines were also reduced in NLRP3e/e
mice receiving tap water only, indicating that NLRP3 might also
play a role in physiological intestinal homeostasis. Of interest,
IL-1b levels in colonic homogenates measured by ELISA did not
differ significantly between WT and NLRP3e/e mice. As
the ELISA does not discriminate between pro-IL-1b and active
IL-1b, we performed western blot analysis for cleaved IL-1b
(p17) and found high levels of cleaved IL-1b in the colon of WT
mice receiving DSS, but not in that of NLRP3e/e mice
(figure 5C).
Figure 4 NLRP3 deficiency and caspase-1 inhibition protects mice from dextran sodium sulfate (DSS)-induced colitis. (A) Loss of basal body weight
and haematochezia score of wild-type (WT) and NLRP3e/e mice (n¼15 per group) receiving 2% DSS or tap water for 9 days. y indicates death rate.
(B) Histological score of distal colon sections of WT and NLRP3e/e mice receiving DSS or tap water on day 6 and day 9 of DSS feeding. (C) Loss of
basal body weight and haematochezia score of WT mice treated with tap water or 2% DSS orally ad libitum in the presence or absence of the caspase-
1-inhibitor pralnacasan (50 mg/kg intraperitoneally) or with Cremophor EL (vehicle) alone. Data are presented as means 6 SEM (n¼2 independent
experiments). *p<0.05.
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DISCUSSION
Data from human specimens and from murine colitis models
indicate that excessive expression of IL-1b and IL-18 plays a key
role in the pathogenesis of IBD.5 31 Furthermore, caspase-1,
which regulates the secretion of biologically active IL-1b and
IL-18, has been identified as a central mediator of DSS-induced
colitis.9 In the present study, we provide evidence that DSS
induces caspase-1 activation via the NLRP3 inflammasome
in macrophages and that NLRP3e/e mice are significantly
protected from DSS-induced colitis, developing a decreased
clinical and histological colitis severity and dramatically reduced
levels of proinflammatory cytokines in the colonic tissue. This
protective effect was most pronounced at an early time point of
the disease, indicating a critical role for the NLRP3 inflamma-
some at the initiation of the inflammatory process. Together,
these results strongly argue for a role for the NLRP3 inflam-
masome in DSS-induced colitis. Interestingly, the clinical colitis
severity parameters in NLRP3e/e mice were comparable with
those achieved by inhibition of caspase-1 with pralnacasan in
WT mice, indicating that pharmacological intervention in the
NLRP3 inflammasome complex may have therapeutic potential
in the treatment of IBD.23
The precise mechanism of NLRP3 inflammasome activation
is incompletely understood. The data obtained in the present
study demonstrate that IL-1b release by macrophages in
response to DSS requires lysosomal maturation, the lysosomal
proteases cathepsin B and cathepsin L, loss of lysosomal integ-
rity as well as ROS production. These mechanisms resemble
those previously described for other NLRP3 stimuli, such as
monosodium urate, asbestos, silica crystals and influenza
virus.21 28 29 Assays measuring IL-1b production by DSS-
stimulated macrophages could be exploited for high-throughput
screening of new anti-inflammatory drugs targeting the NLRP3
inflammasome for the treatment of IBD.
In what respect can these findings contribute to our under-
standing of human IBD? Genetic studies provide evidence for an
association of IBD with mutations of NLRP3 inflammasome
components. Villani and co-workers found that susceptibility to
Crohn’s disease is associated with polymorphisms located in
a predicted regulatory region on chromosome 1q44 downstream
of NLRP3.16 Interestingly, these polymorphisms correlated with
impairment of IL-1b processing of PBMCs in response to LPS,
indicating that NLRP3-mediated caspase-1 activation may play
a protective role in IBD, for example in the defence of intestinal
microbial pathogens. On the other hand, McGovern and co-
workers detected an association between IBD and a poly-
morphism of CARD8 (C10X),32 even though this could not be
confirmed by others.33 34 CARD8 is a binding partner of NLRP3
and as such a component of the NLRP3 inflammasome.35 It is
known to suppress NF-kB activity and to regulate caspase-1
activation.36 37 Similarly to mutations in NOD2, CARD8
mutations might lead to perturbations in the NF-kB pathway,
finally leading to upregulation of pro-IL-1b and pro-IL-18 in
lamina propria macrophages. In the same model, an additional
gain-of-function mutation of NLRP3 could lead to an over-
activated caspase-1, cleaving pro-IL-1b and pro-IL-18 into their
biologically active forms. In support of this hypothesis, Schoultz
and co-workers have recently reported that combined NLRP3
and CARD8 mutations increase the susceptibility to Crohn’s
disease in a cohort of Swedish men.17
This ‘two-hit’ model of caspase-1 activation leading to the
secretion of IL-1b and IL-18 in human IBD appears to be closely
mirrored in the DSS colitis model in mice. Initially, DSS exerts
a direct toxic effect on the epithelial barrier, hence allowing
bacteria to stimulate lamina propria macrophages via TLRs and
the NF-kB pathway, which leads to enhanced transcription
of pro-IL-1b and pro-IL-18.38 In a second step, DSS induces
caspase-1 activation via the NLRP3 inflammasome complex,
cleaving IL-1b and IL-18 into their biologically active forms,
which initiates an intestinal inflammatory cascade. Our data
may thus help to understand why DSS-induced colitis is, despite
its striking simplicity, such a valuable model of IBD.
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Figure 5 Reduced inflammatory responses in NLRP3e/e mice in response to dextran sodium sulfate (DSS). (A) Peritoneal macrophages of wild-type
(WT) and NLRP3e/e mice (n¼5 per group) treated with 2% DSS for 9 days or with tap water were obtained by lavage, and spontaneous release of
interleukin 1b (IL-1b) was determined in culture supernatant by ELISA. (B) Cytokine levels in colonic homogenate of WT and NLRP3e/e mice. Levels of
IL-1b, tumour necrosis factor a (TNFa) and interferon g (IFNg) were analysed by ELISA. IP-10 expression was assessed by quantitative reverse
transcriptionePCR. Data are presented as means 6 SEM (n¼2 independent experiments). *p<0.05. (C) Western blots of IL-1b (p17) in colonic
homogenate of DSS-treated WT and NLRP3e/e mice.
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